Eric C. Wang
Research Subjects
Eric C. Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Jiyong Hong
Department of Chemistry, Duke University, Durham, USA
2 shared publications - Chris Han
Department of Chemistry
1 shared publication - Hyoungsu Kim
Department of Pharmacy and Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Suwon 16499, Republic of Korea
1 shared publication Iljin Shin
Department of Chemistry
1 shared publication- Jinjae Park
Department of Chemistry, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea
1 shared publication - Pyeonghwa Jeong
Department of Chemistry, Duke University, Durham, NC, 27708
1 shared publication
Latest Publications
- Open Access
- 2 October 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (40) , 47623-47630
Asymmetric Synthesis of the TRPV1 Modulator AMG8562 via Lipase-Catalyzed Kinetic Resolution
The transient receptor potential vanilloid-1 (TRPV1) channel is a key mediator of pain perception and responds to various stimuli such as heat, low pH, and inflammation. Among TRPV1 antagonists, (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)-phenyl)-acrylamide (AMG8562) shows promise as a nonopioid analgesic, attenuating pain behaviors in rodent models without eliciting hyperthermic side effects commonly associated with other TRPV1 antagonists. Despite its potential, there has been limited research regarding the synthesis of AMG8562. Here, we present an asymmetric synthesis of AMG8562 featuring a lipase-catalyzed kinetic resolution of racemic 4-nitroindan-2-ol. This approach enables scalable access to enantiomerically pure material and provides a platform for the synthesis of structurally diverse AMG8562 analogues with potential for improved pharmacological properties.
- 2 October 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (40) , 47623-47630
Open AccessAsymmetric Synthesis of the TRPV1 Modulator AMG8562 via Lipase-Catalyzed Kinetic Resolution
The transient receptor potential vanilloid-1 (TRPV1) channel is a key mediator of pain perception and responds to various stimuli such as heat, low pH, and inflammation. Among TRPV1 antagonists, (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)-phenyl)-acrylamide (AMG8562) shows promise as a nonopioid analgesic, attenuating pain behaviors in rodent models without eliciting hyperthermic side effects commonly associated with other TRPV1 antagonists. Despite its potential, there has been limited research regarding the synthesis of AMG8562. Here, we present an asymmetric synthesis of AMG8562 featuring a lipase-catalyzed kinetic resolution of racemic 4-nitroindan-2-ol. This approach enables scalable access to enantiomerically pure material and provides a platform for the synthesis of structurally diverse AMG8562 analogues with potential for improved pharmacological properties.
- 12 September 2025
- Published by American Chemical Society (ACS) in Organic Letters
Asymmetric Total Synthesis of Daucane-Type Sesquiterpenoids (+)-Ferutinin and (+)-Kuhistanicaol G
Given the poor outcomes associated with current pancreatic cancer therapies, the "antiausterity" activity of ferutinin and kuhistanicaol G is particularly encouraging. The asymmetric syntheses of (+)-ferutinin and (+)-kuhistanicaol G are achieved through a sequence involving tandem radical addition/allylation, chelation-controlled nucleophilic addition, and Chugaev elimination. This synthetic strategy enables the efficient construction of appropriately functionalized 5,7-fused daucane skeletons. Our work paves the way for the development of new pancreatic cancer therapeutics and provides access to chemical probes for elucidating mechanisms of action.
- 12 September 2025
- Published by American Chemical Society (ACS) in Organic Letters
Asymmetric Total Synthesis of Daucane-Type Sesquiterpenoids (+)-Ferutinin and (+)-Kuhistanicaol G
Given the poor outcomes associated with current pancreatic cancer therapies, the "antiausterity" activity of ferutinin and kuhistanicaol G is particularly encouraging. The asymmetric syntheses of (+)-ferutinin and (+)-kuhistanicaol G are achieved through a sequence involving tandem radical addition/allylation, chelation-controlled nucleophilic addition, and Chugaev elimination. This synthetic strategy enables the efficient construction of appropriately functionalized 5,7-fused daucane skeletons. Our work paves the way for the development of new pancreatic cancer therapeutics and provides access to chemical probes for elucidating mechanisms of action.